RNS Number: 6864 E Hikma Pharmaceuticals Plc 08 July 2019 London, 8 July 2019- Hikma Pharmaceuticals PLC will announce its interim financial results for the six months ended 30 June 2019 on Friday 09 August 2019.. United Kingdom 0800 640 6441. United Kingdom 020 3936 2999.

RNS Number: 2731 E Hikma Pharmaceuticals Plc 02 July 2019. LONDON, 2 July 2019- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 30 June 2019, its share capital consists of 242,265,327 ordinary shares with voting rights. We're a global company with a local presence across the United...

RNS Number: 9893 A Hikma Pharmaceuticals Plc 03 June 2019. LONDON, 3 June 2019- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 31 May 2019, its share capital consists of 242,241,495 ordinary shares with voting rights. We're a global company with a local presence across the United States,...

LONDON, 17 May 2019- Hikma Pharmaceuticals PLC announces its Annual General Meeting, held at Sofitel St James, 6 Waterloo Place, London SW1Y 4 AN on 17 May 2019 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds...

LONDON, 17 May 2019: Hikma Pharmaceuticals PLC announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan to Persons Discharging Managerial Responsibility of the Company.. Awards under the EIP were made on 12 March 2019 at a price of 1,763 pence per Ordinary Share as...

RNS Number: 3320 Z Hikma Pharmaceuticals Plc 17 May 2019 London, 17 May 2019- Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, will hold its Annual General Meeting today and provide an update on recent trading.. Siggi Olafsson, Hikma's CEO, said: "We are pleased to be holding our Annual General Meeting today, which will include a review of the...

RNS Number: 8216 X Hikma Pharmaceuticals Plc 01 May 2019. LONDON, 1 April 2019- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 30 April 2019, its share capital consists of 241,953,780 ordinary shares with voting rights. We're a global company with a local presence across the United...

RNS Number: 6420 X Hikma Pharmaceuticals Plc 01 May 2019 London, 1 May 2019- Hikma Pharmaceuticals PLC the multinational pharmaceutical company, today launched its 100 th injectable medicine in the United States with the introduction of Vancomycin Hydrochloride for Injection, USP, 5 g, 10 g and 750 mg, through its US affiliate, Hikma Pharmaceuticals USA Inc. 1.

RNS Number: 2519 W Hikma Pharmaceuticals Plc 15 April 2019. LONDON, 15 April 2019: Hikma Pharmaceuticals PLC announces that the following Persons Discharging Managerial Responsibility have received shares as a result of the vesting of their conditional share awards on 13 April 2017 under the 2014 Executive Incentive Plan Element B which was completed on 15...

RNS Number: 2242 W Hikma Pharmaceuticals Plc 15 April 2019. In compliance with Listing Rule 9.6. 1 of the UK Financial Conduct Authority, the aforementioned documents will be submitted to the UK Listing Authority and will be available for public inspection at the National Storage Mechanism www.morningstar.co.uk/uk/NSM. The Company's Annual General...

RNS Number: 7503 U Hikma Pharmaceuticals Plc 01 April 2019. LONDON, 1 April 2019- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 31 March 2019, its share capital consists of 241,629,880 ordinary shares with voting rights. We're a global company with a local presence across the United...

RNS Number: 7455 U Hikma Pharmaceuticals Plc 01 April 2019. Block Listing Six Monthly Return. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 2004 T Hikma Pharmaceuticals Plc 18 March 2019. LONDON, 18 March 2019: Hikma Pharmaceuticals PLC announces that the following Persons Discharging Managerial Responsibility have received shares as a result of the vesting of their conditional share awards on 17 March 2016 under the 2014 Executive Incentive Plan which was completed on 18 March 2019.

RNS Number: 0300 T Hikma Pharmaceuticals Plc 15 March 2019 Notification and public disclosure of transactions by persons discharging managerial responsibilities. Peter Speirs Company Secretary, responsible for releasing this announcement +44 20 7399 2760. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

RNS Number: 8710 S Hikma Pharmaceuticals Plc 14 March 2019 Notification and public disclosure of transactions by persons discharging managerial responsibilities. Peter Speirs Company Secretary, responsible for releasing this announcement +44 20 7399 2760. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

RNS Number: 7823 S Hikma Pharmaceuticals Plc 13 March 2019 Notification and public disclosure of transactions by persons discharging managerial responsibilities. Peter Speirs Company Secretary, responsible for releasing this announcement +44 20 7399 2760. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

RNS Number: 7822 S Hikma Pharmaceuticals Plc 13 March 2019 Notification and public disclosure of transactions by persons discharging managerial responsibilities. Peter Speirs Company Secretary, responsible for releasing this announcement +44 20 7399 2760. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the...

Hikma Pharmaceuticals Plc (HIK.L) Announced, in its final results for the year ended 31 December 2018, that revenues rose to $2,070.0 million from $1,936.0 million recorded in the previous year. Profit after tax stood at $285.0 million, compared to a loss of $839.0 million. The Board is recommending a final dividend of 26c per share (approximately 20p per share) (2017: 23c per share) bringing the total dividend for the full year to 38c per share (approximately 29p per share) (2017: 34c per share, approximately 24p per share).

RNS Number: 6734 S Hikma Pharmaceuticals Plc 13 March 2019 London, 13 March 2019- Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2018.. ·Group core revenue of $2,076 million, up 7%. ·Group core operating profit of $460 million, up 19%.

Hikma Pharmaceuticals Plc (HIK.L) Announced the appointment of Cynthia Schwalm as an Independent Non-Executive Director effective 1 June 2019